Abbott has made significant strides in the field of electrophysiology, announcing two major developments to support its pulsed field ablation (PFA) technology for treating abnormal heart rhythms, such as atrial fibrillation. The company completed early enrollment in the VOLT-AF IDE study, which evaluates the Volt PFA System, and launched the FOCALFLEX trial to assess the TactiFlex Duo Ablation Catheter, Sensor Enabled. These advancements mark an important step forward in developing innovative PFA catheters that offer safety and efficacy advantages over traditional ablation methods, such as radiofrequency (RF) and cryogenic ablation. Abbott’s systems aim to improve procedural outcomes by addressing limitations in first-generation PFA technologies, including better visualization and contact accuracy.
Abbott, a global leader in healthcare technology, continues to drive innovation across multiple fields, including diagnostics and medical devices. Its electrophysiology solutions leverage advanced heart mapping systems, such as the newly FDA-cleared Advisor HD Grid X Mapping Catheter, Sensor Enabled, which supports both PFA and RF ablation procedures. With a portfolio that spans across 160 countries, Abbott is committed to improving patient outcomes by delivering cutting-edge solutions, serving the evolving needs of the medical community.
